Private company

Myovant Sciences Ltd.

American pharmaceutical preparations company, incorporated in California. Summary from the record

Last updated Oct 19, 2026.

Overview

$231.0MRevenue, fiscal 20222
-$206.0MNet income, fiscal 20222
  • IndustryPharmaceutical Preparations1
  • HeadquartersLondon, United Kingdom1
  • Incorporated inCA3
  • Business addressSuite 1, 3Rd Floor, 11-12 St. James Square, London, X0 Sw1Y 4Lb3
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-81.1%Operating margin2
-89.2%Net margin2
289.4%Revenue growth, 20222
-$269.5MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development28¢$107.4M
  • Selling, general and admin67¢$259.4M
  • Interest4¢$14.0M
  • Income tax1¢$5.0M

Out of $231.0M in revenue.2 The company lost money this year.

Financial statements

Revenue42$231.0M in 2022
0$100.0M$200.0M$300.0M2019: $0$020192020: $0$020202021: $59.3M$59.3M20212022: $231.0M$231.0M2022+289%
Operating income542-$187.3M in 2022+124% since 2017
-$300.0M-$200.0M-$100.0M02017: -$83.5M-$83.5M20172018: -$143.0M-$143.0M2018+71%2019: -$264.8M-$264.8M2019+85%2020: -$274.9M-$274.9M2020+4%2021: -$260.8M-$260.8M2021−5%2022: -$187.3M-$187.3M2022−28%
Net income5642-$206.0M in 2022+147% since 2017
-$300.0M-$200.0M-$100.0M02017: -$83.4M-$83.4M20172018: -$143.3M-$143.3M2018+72%2019: -$273.6M-$273.6M2019+91%2020: -$289.0M-$289.0M2020+6%2021: -$255.1M-$255.1M2021−12%2022: -$206.0M-$206.0M2022−19%
Fiscal year2016201720182019202020212022
Revenue$04$02$59.3M2$231.0M2
Research and development$43.5M5$116.8M6$222.6M4$192.6M2$136.7M2$107.4M2
Selling, general and admin$42.2M4$82.3M2$181.4M2$259.4M2
Operating income-$83.5M5-$143.0M5-$264.8M4-$274.9M2-$260.8M2-$187.3M2
Interest$05$2.0M5$8.8M4$12.7M2$10.4M2$14.0M2
Income before tax-$200.9M2
Income tax-$74.0K5$213.0K6$476.0K4$761.0K2$336.0K2$5.0M2
Net income-$83.4M5-$143.3M6-$273.6M4-$289.0M2-$255.1M2-$206.0M2
Earnings per share-$3.372-$2.832-$2.222
Earnings per share (diluted)-$3.372-$2.832-$2.222
Shares (weighted, basic)93.0M shares2
Shares (weighted, diluted)93.0M shares2

Compare Myovant Sciences Ltd. with another company

Leadership

Who has led Myovant Sciences Ltd., and when. Pick a name to see everywhere that person has worked.

Board members and other officers (23)

Filings

128 filings to the SEC since October 2021: 1 annual reports, 5 quarterly reports, 14 major events, 65 insider forms, 13 large holders, 30 other. The latest 20:

  1. Mar 20, 202315-12G EDGAR
  2. Mar 16, 2023EFFECT EDGAR
  3. Mar 16, 2023EFFECT EDGAR
  4. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  5. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  6. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  7. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  8. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  9. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  10. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  11. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  12. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  13. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  14. Mar 10, 2023SC 13D/A EDGAR
  15. Mar 10, 2023S-8 POS EDGAR
  16. Mar 10, 2023S-8 POS EDGAR
  17. Mar 10, 2023S-8 POS EDGAR
  18. Mar 10, 2023S-8 POS EDGAR
  19. Mar 10, 2023S-8 POS EDGAR
  20. Mar 10, 2023S-8 POS EDGAR

The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

38 open-market trades by officers, directors and large owners since October 2021: 1 buys and 37 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 10, 2023Sumitomo Chemical Co., Ltd.10% ownerBuy51,599,200$27.00$1.4BForm 4
Jan 18, 2023Lang MatthewGeneral Counsel & Corp. Secy.Sale1,272$26.89$34.2KForm 4
Jan 18, 2023Merendino LaurenChief Commercial OfficerSale2,008$26.89$54.0KForm 4
Jan 18, 2023Marek David CPrincipal Executive OfficerSale8,037$26.89$216.1KForm 4
Jan 18, 2023Arjona Ferreira Juan CamiloChief Medical OfficerSale1,109$26.89$29.8KForm 4
Jan 4, 2023Arjona Ferreira Juan CamiloChief Medical OfficerSale2,251$26.90$60.6KForm 4
Jan 4, 2023Lang MatthewGeneral Counsel & Corp. Secy.Sale2,779$26.90$74.8KForm 4
Dec 16, 2022Mehra UneekPrincipal Financial OfficerSale2,241$26.75$59.9KForm 4
Oct 18, 2022Merendino LaurenChief Commercial OfficerSale1,703$25.20$42.9KForm 4
Oct 18, 2022Marek David CPrincipal Executive OfficerSale11,156$25.20$281.1KForm 4
Oct 18, 2022Lang MatthewGeneral Counsel & Corp. Secy.Sale1,933$25.20$48.7KForm 4
Oct 18, 2022Arjona Ferreira Juan CamiloChief Medical OfficerSale1,604$25.20$40.4KForm 4
Oct 4, 2022Arjona Ferreira Juan CamiloChief Medical OfficerSale2,738$24.40$66.8KForm 4
Oct 4, 2022Lang MatthewGeneral Counsel & Corp. Secy.Sale3,679$24.40$89.8KForm 4
Sep 16, 2022Mehra UneekPrincipal Financial OfficerSale9,243$18.86$174.3KForm 4
Aug 15, 2022Lang MatthewGeneral Counsel & Corp. Secy.Sale31,214$18.23$569.0KForm 4
Jul 18, 2022Lang MatthewGeneral Counsel & Corp. Secy.Sale1,935$12.87$24.9KForm 4
Jul 18, 2022Merendino LaurenChief Commercial OfficerSale1,704$12.87$21.9KForm 4
Jul 18, 2022Marek David CPrincipal Executive OfficerSale11,164$12.87$143.7KForm 4
Jul 18, 2022Arjona Ferreira Juan CamiloChief Medical OfficerSale1,606$12.87$20.7KForm 4

All 38 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37